{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:14:39Z","timestamp":1788909279853,"version":"build-2803163510"},"reference-count":39,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.3892\/or.2014.3665","type":"journal-article","created":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T09:35:13Z","timestamp":1418290513000},"page":"526-532","source":"Crossref","is-referenced-by-count":17,"title":["Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib"],"prefix":"10.3892","volume":"33","author":[{"given":"XINZHAO","family":"WANG","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HONGKUAN","family":"SONG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QIAN","family":"YU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"QI","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"LEILEI","family":"WANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZHAOYUN","family":"LIU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZHIYONG","family":"YU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2014,12,11]]},"reference":[{"key":"key20180107213423_b1-or-33-02-0526","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.molonc.2010.04.006","article-title":"Triple-negative breast cancer: present challenges and new perspectives","volume":"4","author":"Podo","year":"2010","journal-title":"Mol Oncol"},{"key":"key20180107213423_b2-or-33-02-0526","first-page":"846","article-title":"New targets for triple-negative breast cancer","volume":"27","author":"Herold","year":"2013","journal-title":"Oncology"},{"key":"key20180107213423_b3-or-33-02-0526","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1200\/JCO.2009.25.4011","article-title":"Emerging targeted therapies for breast cancer","volume":"28","author":"Alvarez","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20180107213423_b4-or-33-02-0526","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-008-0206-z","article-title":"Invasive ductal carcinoma of the breast with the \u2018triple-negative\u2019 phenotype: prognostic implications of EGFR immunoreactivity","volume":"116","author":"Viale","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107213423_b5-or-33-02-0526","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin Cancer Res"},{"key":"key20180107213423_b6-or-33-02-0526","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2004.07.215","article-title":"Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2","volume":"22","author":"Herbst","year":"2004","journal-title":"J Clin Oncol"},{"key":"key20180107213423_b7-or-33-02-0526","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s10549-004-1720-2","article-title":"A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer","volume":"89","author":"von Minckwitz","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107213423_b8-or-33-02-0526","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1200\/JCO.2005.11.890","article-title":"Critical update and emerging trends in epidermal growth factor receptor targeting in cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107213423_b9-or-33-02-0526","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1200\/JCO.2005.08.326","article-title":"Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20180107213423_b10-or-33-02-0526","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1634\/theoncologist.8-6-576","article-title":"Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors","volume":"8","author":"Janmaat","year":"2003","journal-title":"Oncologist"},{"key":"key20180107213423_b11-or-33-02-0526","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/jcp.20588","article-title":"The MEK\/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib","volume":"207","author":"Normanno","year":"2006","journal-title":"J Cell Physiol"},{"key":"key20180107213423_b12-or-33-02-0526","first-page":"3","article-title":"An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa\u2122)-induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review)","volume":"20","author":"Ferrer-Soler","year":"2007","journal-title":"Int J Mol Med"},{"key":"key20180107213423_b13-or-33-02-0526","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrc864","article-title":"Live or let die: the cell\u2019s response to p53","volume":"2","author":"Vousden","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"key20180107213423_b14-or-33-02-0526","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1002\/humu.20495","article-title":"Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database","volume":"28","author":"Petitjean","year":"2007","journal-title":"Hum Mutat"},{"key":"key20180107213423_b15-or-33-02-0526","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/nrc2693","article-title":"When mutants gain new powers: news from the mutant p53 field","volume":"9","author":"Brosh","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"key20180107213423_b16-or-33-02-0526","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s10549-012-2092-7","article-title":"Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer","volume":"134","author":"Grob","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"key20180107213423_b17-or-33-02-0526","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","year":"2012","journal-title":"Nature"},{"key":"key20180107213423_b18-or-33-02-0526","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/nature08989","article-title":"Genome remodelling in a basal-like breast cancer metastasis and xenograft","volume":"464","author":"Ding","year":"2010","journal-title":"Nature"},{"key":"key20180107213423_b19-or-33-02-0526","doi-asserted-by":"crossref","first-page":"7071","DOI":"10.1158\/0008-5472.CAN-11-0128","article-title":"p53 modulates acquired resistance to EGFR inhibitors and radiation","volume":"71","author":"Huang","year":"2011","journal-title":"Cancer Res"},{"key":"key20180107213423_b20-or-33-02-0526","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/sj.gt.3300914","article-title":"Induction of apoptosis and G2\/M arrest by infection with replication-deficient adenovirus at high multiplicity of infection","volume":"6","author":"Brand","year":"1999","journal-title":"Gene Ther"},{"key":"key20180107213423_b21-or-33-02-0526","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/35042675","article-title":"Surfing the p53 network","volume":"408","author":"Vogelstein","year":"2000","journal-title":"Nature"},{"key":"key20180107213423_b22-or-33-02-0526","doi-asserted-by":"crossref","first-page":"6550","DOI":"10.1158\/0008-5472.CAN-08-0137","article-title":"Peptide aptamers targeting mutant p53 induce apoptosis in tumor cells","volume":"68","author":"Guida","year":"2008","journal-title":"Cancer Res"},{"key":"key20180107213423_b23-or-33-02-0526","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1038\/sj.onc.1210295","article-title":"Reactivation of mutant p53: molecular mechanisms and therapeutic potential","volume":"26","author":"Selivanova","year":"2007","journal-title":"Oncogene"},{"key":"key20180107213423_b24-or-33-02-0526","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2119\/molmed.2011.00217","article-title":"Microglial stimulation of glioblastoma invasion involves epidermal growth factor receptor (EGFR) and colony stimulating factor 1 receptor (CSF-1R) signaling","volume":"18","author":"Coniglio","year":"2012","journal-title":"Mol Med"},{"key":"key20180107213423_b25-or-33-02-0526","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"key":"key20180107213423_b26-or-33-02-0526","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1038\/sj.onc.1206388","article-title":"Loss of PTEN\/MMAC1\/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors","volume":"22","author":"Bianco","year":"2003","journal-title":"Oncogene"},{"key":"key20180107213423_b27-or-33-02-0526","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/jcmm.12046","article-title":"Inhibition of the PI3K\/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer","volume":"17","author":"Yi","year":"2013","journal-title":"J Cell Mol Med"},{"key":"key20180107213423_b28-or-33-02-0526","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1535-7163.MCT-07-0004","article-title":"The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway","volume":"6","author":"Elrod","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"key20180107213423_b29-or-33-02-0526","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/j.bbamcr.2006.10.001","article-title":"Roles of the Raf\/MEK\/ERK pathway in cell growth, malignant transformation and drug resistance","volume":"1773","author":"McCubrey","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"key20180107213423_b30-or-33-02-0526","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.molcel.2011.04.017","article-title":"Two phases of mitogenic signaling unveil roles for p53 and EGR1 in elimination of inconsistent growth signals","volume":"42","author":"Zwang","year":"2011","journal-title":"Mol Cell"},{"key":"key20180107213423_b31-or-33-02-0526","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/cgt.2008.100","article-title":"P53 and PTEN expression contribute to the inhibition of EGFR downstream signaling pathway by cetuximab","volume":"16","author":"Bouali","year":"2009","journal-title":"Cancer Gene Ther"},{"key":"key20180107213423_b32-or-33-02-0526","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1158\/0008-5472.CAN-06-2712","article-title":"Mitogen-activated protein kinase kinase inhibition enhances nuclear proapoptotic function of p53 in acute myelogenous leukemia cells","volume":"67","author":"Kojima","year":"2007","journal-title":"Cancer Res"},{"key":"key20180107213423_b33-or-33-02-0526","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ejphar.2008.10.024","article-title":"An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells","volume":"600","author":"Chang","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"key20180107213423_b34-or-33-02-0526","doi-asserted-by":"crossref","first-page":"184","DOI":"10.4062\/biomolther.2014.026","article-title":"\u03b2-lapachone-induced apoptosis of human gastric carcinoma AGS cells is caspase-dependent and regulated by the PI3K\/Akt pathway","volume":"22","author":"Yu","year":"2014","journal-title":"Biomol Ther"},{"key":"key20180107213423_b35-or-33-02-0526","first-page":"1665","article-title":"Adenoviral-mediated wild-type p53 gene expression sensitizes colorectal cancer cells to ionizing radiation","volume":"2","author":"Spitz","year":"1996","journal-title":"Clin Cancer Res"},{"key":"key20180107213423_b36-or-33-02-0526","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/JCO.2003.21.13.2508","article-title":"Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results","volume":"21","author":"Lang","year":"2003","journal-title":"J Clin Oncol"},{"key":"key20180107213423_b37-or-33-02-0526","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1200\/JCO.2001.19.6.1750","article-title":"Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study","volume":"19","author":"Schuler","year":"2001","journal-title":"J Clin Oncol"},{"key":"key20180107213423_b38-or-33-02-0526","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/sj.cgt.7700472","article-title":"A phase I\/II trial of rAd\/p53 (SCH 58500) gene replacement in recurrent ovarian cancer","volume":"9","author":"Buller","year":"2002","journal-title":"Cancer Gene Ther"},{"key":"key20180107213423_b39-or-33-02-0526","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1200\/JCO.2008.18.9670","article-title":"Effect of recombinant adenovirus- p53 combined with radiotherapy on long-term prognosis of advanced nasopharyngeal carcinoma","volume":"27","author":"Pan","year":"2009","journal-title":"J Clin Oncol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2014.3665\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T10:02:53Z","timestamp":1566122573000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2014.3665"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,11]]},"references-count":39,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,12,11]]},"published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.3892\/or.2014.3665"],"URL":"https:\/\/doi.org\/10.3892\/or.2014.3665","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,11]]}}}